John Montana, Calluna CEO
January 22, 2024 04:00 AM ESTUpdated 09:26 AM
Financing
Deals

Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

Anna Brown

News Reporter

A merg­er be­tween Ox­i­tope Phar­ma and Arxx Ther­a­peu­tics sees the birth of clin­i­cal-stage im­munother­a­py com­pa­ny Cal­lu­na, with €75 mil­lion ($81.6 mil­lion) in its pock­ets from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times